Literature DB >> 16800736

Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins.

Chistina V Obiezu1, Iacovos P Michael, Michael A Levesque, Eleftherios P Diamandis.   

Abstract

Human kallikrein 4 (hK4) is a member of the expanded family of human kallikreins, a group of 15 secreted proteases. While this protein has been associated with ovarian and prostate cancer prognosis, only limited functional information exists. Therefore, we have undertaken an investigation of its enzymatic properties regarding substrate preference, degradation of extracellular matrix proteins, and its inhibition by various inhibitors. We successfully expressed and purified active recombinant hK4 from supernatants of the Pichia pastoris expression system. This enzyme seems to cleave more efficiently after Arg compared to Lys at the P1 position and exhibits modest specificity for amino acids at positions P2 and P3. hK4 forms complexes with alpha1-antitrypsin, alpha2-antiplasmin and alpha2-macroglobulin. The protease mediates limited degradation of extracellular matrix proteins such as collagen I and IV, and more efficient degradation of the alpha-chain of fibrinogen. The cleavage of extracellular matrix proteins by hK4 suggests that this enzyme may play a role in tissue remodeling and cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16800736     DOI: 10.1515/BC.2006.094

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  13 in total

Review 1.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

Review 2.  Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.

Authors:  Michael Blaber; Hyesook Yoon; Maria A Juliano; Isobel A Scarisbrick; Sachiko I Blaber
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

Review 3.  Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.

Authors:  Ignacio Blanco; Beatriz Lara; Frederick de Serres
Journal:  Orphanet J Rare Dis       Date:  2011-04-12       Impact factor: 4.123

Review 4.  Functions of KLK4 and MMP-20 in dental enamel formation.

Authors:  Yuhe Lu; Petros Papagerakis; Yasuo Yamakoshi; Jan C-C Hu; John D Bartlett; James P Simmer
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

5.  Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network.

Authors:  Joakim E Swedberg; Simon J de Veer; Kei C Sit; Cyril F Reboul; Ashley M Buckle; Jonathan M Harris
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

Review 6.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

Review 7.  Dental enamel development: proteinases and their enamel matrix substrates.

Authors:  John D Bartlett
Journal:  ISRN Dent       Date:  2013-09-16

8.  Hydrogel Microwell Arrays Allow the Assessment of Protease-Associated Enhancement of Cancer Cell Aggregation and Survival.

Authors:  Daniela Loessner; Stefan Kobel; Judith A Clements; Matthias P Lutolf; Dietmar W Hutmacher
Journal:  Microarrays (Basel)       Date:  2013-08-22

9.  Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.

Authors:  Ying Dong; Carson Stephens; Carina Walpole; Joakim E Swedberg; Glen M Boyle; Peter G Parsons; Michael A McGuckin; Jonathan M Harris; Judith A Clements
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

Review 10.  Metastasis of ovarian cancer is mediated by kallikrein related peptidases.

Authors:  Ying Dong; Daniela Loessner; Helen Irving-Rodgers; Andreas Obermair; James L Nicklin; Judith A Clements
Journal:  Clin Exp Metastasis       Date:  2013-09-17       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.